Pyruvate Kinase Deficiency

• EMA approval · 2026-04-21
  EMA Authorised: Pyrukynd (mitapivat sulfate) — Agios Netherlands B.V.

  The European Medicines Agency authorised Pyrukynd (mitapivat) for the treatment of pyruvate kinase deficiency—a genetic cause of hemolytic a…

• FDA approval · 2025-12-23
  FDA Approved: AQVESME — Supplemental Application (Agios Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for AQVESME (mitapivat) submitted by Agios Pharmaceuticals, Inc.

• FDA approval · 2022-02-17
  FDA Approved: AQVESME — Original Application (Agios Pharmaceuticals, Inc.)

  FDA approved AQVESME (mitapivat) from Agios Pharmaceuticals as the original application for the treatment of pyruvate kinase deficiency.